Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Oligodendroglioma 1Medulloblastoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Familial ependymoma 1Ependymoma 1Drug-Related Side Effects and Adverse Reactions 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 38Radiotherapy 21Radiosurgery 21Irinotecan 11Cyclophosphamide 11Radiation 10Magnetic Resonance Spectroscopy 10Etoposide 10Surgical Procedures, Operative 9Erlotinib Hydrochloride 9Carmustine 9Filgrastim 8Carboplatin 8pembrolizumab 7Bevacizumab 7Vincristine 6Sorafenib 6O(6)-benzylguanine 6Nivolumab 6Flucytosine 6Aminolevulinic Acid 6temsirolimus 5sargramostim 5Vorinostat 5Trastuzumab 5Topotecan 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Everolimus 5cediranib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Brain Neoplasms × Procarbazine × Clear all
NCT00005796 2015-03-25

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

Indiana University

Phase 1 Completed
10 enrolled
CNSSarcoma

Familial ependymoma, Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡